The estimated Net Worth of Casey Lynch is at least $5.42 Million dollars as of 18 November 2021. Ms Lynch owns over 60,000 units of Cortexyme Inc stock worth over $214,295 and over the last 5 years she sold CRTX stock worth over $4,414,500. In addition, she makes $787,500 as Co-Founder, Chairman, and Pres & CEO at Cortexyme Inc.
Ms has made over 4 trades of the Cortexyme Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she exercised 60,000 units of CRTX stock worth $27,600 on 18 November 2021.
The largest trade she's ever made was exercising 60,000 units of Cortexyme Inc stock on 18 November 2021 worth over $27,600. On average, Ms trades about 25,714 units every 41 days since 2020. As of 18 November 2021 she still owns at least 109,895 units of Cortexyme Inc stock.
You can see the complete history of Ms Lynch stock trades at the bottom of the page.
Casey C. Lynch is the Co-Founder, Chairman, Pres & CEO at Cortexyme Inc.
As the Co-Founder, Chairman, and Pres & CEO of Cortexyme Inc, the total compensation of Ms Lynch at Cortexyme Inc is $787,500. There are 2 executives at Cortexyme Inc getting paid more, with Michael Detke having the highest compensation of $1,100,170.
Ms Lynch is 47, she's been the Co-Founder, Chairman, and Pres & CEO of Cortexyme Inc since . There are 16 older and 2 younger executives at Cortexyme Inc. The oldest executive at Cortexyme Inc is Una Ryan, 78, who is the Lead Independent Director.
Casey's mailing address filed with the SEC is C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO, CA, 94080.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi, and Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: